PTC Therapeutics Inc (PTCT) Stock Analysis
Verdict: WATCH (do not buy)
Commercial rare-disease cash flow de-risks pipeline, but $2.7B debt and restructuring-driven margin volatility cap near-term upside.
Investment score: 58/100
Analysis as of
Is PTC Therapeutics Inc stock worth reviewing? The TradeMates thesis
The model evaluates PTCT as a Hold at $68.22. Solid commercial rare-disease revenue and positive earnings beats are counterbalanced by a $2.71B debt burden and persistent insider selling.
7-factor investment score
- Valuation: 62/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 52/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
PTC Therapeutics Inc opportunities and risks
What speaks for PTCT
- Oral Huntington's Candidate (PTC518) Pipeline Value
What speaks against PTCT
- $2.71B Debt Load Creates Negative Equity
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PTCT | n/a | 5.6x | 30.8x | 82.1% | -3.8% | -5.8% |
| ORKA | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.7% |
| SRRK | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.0% |
| TVTX | n/a | 10.2x | 4237.6x | 94.4% | -7.4% | 0.9% |
| DNTH | n/a | 3035.7x | n/a | 96.0% | -1570.9% | -2.7% |
| COGT | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.7% |
Frequently asked questions about PTC Therapeutics Inc (PTCT)
Is PTCT stock a good investment?
The TradeMates model rates PTC Therapeutics Inc as WATCH (do not buy) with an investment score of 58/100. The model evaluates PTCT as a Hold at $68.22. Solid commercial rare-disease revenue and positive earnings beats are counterbalanced by a $2.71B debt burden and persistent insider selling. This is algorithmic model output, not personal investment advice.
Is PTCT stock a buy?
The TradeMates model verdict for PTCT is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.